Abstract
To the Editor: We read with great interest the article by Wilson and coworkers,1 in which levels of β2-microglobulin (B2M) were demonstrated to correlate closely with the severity of peripheral arterial disease (PAD). Interestingly, the corresponding editorial2 mentioned several factors that could potentially limit the routine administration of B2M to measure peripheral artery disease (PAD) in patients and also stated that no one would have chosen B2M as a candidate marker before this proteomic approach. We think the opposite is the case; …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
